What is Wedbush’s Estimate for VIGL FY2029 Earnings?

Vigil Neuroscience, Inc. (NASDAQ:VIGL) – Stock analysts at Wedbush issued their FY2029 earnings per share estimates for Vigil Neuroscience in a research report issued to clients and investors on Thursday, March 13th. Wedbush analyst L. Chico expects that the company will post earnings per share of $1.40 for the year. Wedbush has a “Outperform” rating and a $13.00 price target on the stock. The consensus estimate for Vigil Neuroscience’s current full-year earnings is ($2.07) per share.

Vigil Neuroscience (NASDAQ:VIGL) last issued its earnings results on Thursday, March 13th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.08).

A number of other research analysts also recently weighed in on VIGL. Guggenheim reissued a “buy” rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. William Blair initiated coverage on Vigil Neuroscience in a research note on Wednesday, December 4th. They issued an “outperform” rating on the stock. JMP Securities restated a “market outperform” rating and set a $22.00 target price on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. Finally, HC Wainwright cut their price target on shares of Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Friday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Vigil Neuroscience currently has an average rating of “Buy” and an average target price of $16.25.

Vigil Neuroscience Price Performance

Shares of NASDAQ VIGL opened at $1.98 on Monday. The company’s 50 day simple moving average is $2.34 and its 200 day simple moving average is $2.77. Vigil Neuroscience has a fifty-two week low of $1.49 and a fifty-two week high of $6.06. The firm has a market capitalization of $80.94 million, a P/E ratio of -0.96 and a beta of 1.82.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VIGL. Cubist Systematic Strategies LLC increased its holdings in shares of Vigil Neuroscience by 53.0% in the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company’s stock worth $41,000 after acquiring an additional 8,358 shares in the last quarter. Northern Trust Corp grew its position in shares of Vigil Neuroscience by 29.0% in the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company’s stock valued at $110,000 after purchasing an additional 14,572 shares during the period. Barclays PLC increased its stake in Vigil Neuroscience by 43.6% during the 4th quarter. Barclays PLC now owns 64,049 shares of the company’s stock worth $109,000 after purchasing an additional 19,436 shares in the last quarter. Two Sigma Investments LP raised its holdings in Vigil Neuroscience by 44.0% during the 4th quarter. Two Sigma Investments LP now owns 136,920 shares of the company’s stock worth $233,000 after buying an additional 41,836 shares during the period. Finally, Jane Street Group LLC bought a new position in Vigil Neuroscience in the fourth quarter valued at approximately $83,000. 83.64% of the stock is currently owned by institutional investors.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.